Furiex Announces Positive Phase II Results for MuDelta

MuDelta, an investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome, met its primary objectives of establishing tolerability, safety and efficacy in a 12-week study.

Drug development and collaboration company Furiex Pharmaceuticals, Inc. announced Tuesday its positive results from Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, an investigational oral agent for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

IBS-D is a common functional bowel disorder that causes chronic diarrhea and abdominal pain.

MuDelta met its primary objectives of establishing tolerability, safety and efficacy in a 12-week randomized, double-blind, placebo-controlled study. The study achieved statistically and clinically significant results for its primary as well as a number of key secondary endpoints. MuDelta also demonstrated durable efficacy through the 12-week treatment period.